Institution
North Tyneside General Hospital
Healthcare•North Shields, England, United Kingdom•
About: North Tyneside General Hospital is a healthcare organization based out in North Shields, England, United Kingdom. It is known for research contribution in the topics: Population & Health care. The organization has 403 authors who have published 421 publications receiving 14731 citations.
Topics: Population, Health care, Randomized controlled trial, Dementia, Stroke
Papers published on a yearly basis
Papers
More filters
••
King's College1, Carlos III Health Institute2, University College London3, Georgia Regents University4, King's College London5, University of North Carolina at Chapel Hill6, University of Naples Federico II7, Southern General Hospital8, Tel Aviv University9, Royal College of Nursing10, Baylor College of Medicine11, Emory University12, University of Cambridge13, North Tyneside General Hospital14, St Thomas' Hospital15, Icahn School of Medicine at Mount Sinai16
TL;DR: An international pilot study assessing feasibility, validity, and acceptability of a nonmotor questionnaire (NMSQuest) found NMS were highly significantly more prevalent across all disease stages and the number of symptoms correlated significantly with advancing disease and duration of disease.
Abstract: Nonmotor symptoms (NMS) of Parkinson's disease (PD) are not well recognized in clinical practice, either in primary or in secondary care, and are frequently missed during routine consultations. There is no single instrument (questionnaire or scale) that enables a comprehensive assessment of the range of NMS in PD both for the identification of problems and for the measurement of outcome. Against this background, a multidisciplinary group of experts, including patient group representatives, has developed an NMS screening questionnaire comprising 30 items. This instrument does not provide an overall score of disability and is not a graded or rating instrument. Instead, it is a screening tool designed to draw attention to the presence of NMS and initiate further investigation. In this article, we present the results from an international pilot study assessing feasibility, validity, and acceptability of a nonmotor questionnaire (NMSQuest). Data from 123 PD patients and 96 controls were analyzed. NMS were highly significantly more prevalent in PD compared to controls (PD NMS, median = 9.0, mean = 9.5 vs. control NMS, median = 5.5, mean = 4.0; Mann-Whitney, Kruskal-Wallis, and t test, P < 0.0001), with PD patients reporting at least 10 different NMS on average per patient. In PD, NMS were highly significantly more prevalent across all disease stages and the number of symptoms correlated significantly with advancing disease and duration of disease. Furthermore, frequently, problems such as diplopia, dribbling, apathy, blues, taste and smell problems were never previously disclosed to the health professionals.
874 citations
••
King's College1, Carlos III Health Institute2, King's College London3, Georgia Regents University4, Baylor College of Medicine5, Osaka University6, Southern General Hospital7, University of Naples Federico II8, Tel Aviv University9, Icahn School of Medicine at Mount Sinai10, St Thomas' Hospital11, Royal College of Nursing12, Emory University13, Fukuoka University14, North Tyneside General Hospital15, University of Kent16, Royal Free Hospital17
TL;DR: NMSS can be used to assess the frequency and severity of NMS in PD patients across all stages in conjunction with the recently validated non‐motor questionnaire.
Abstract: Non-motor symptoms (NMS) in Parkinson's disease (PD) are common, significantly reduce quality of life and at present there is no validated clinical tool to assess the progress or potential response to treatment of NMS. A new 30-item scale for the assessment of NMS in PD (NMSS) was developed. NMSS contains nine dimensions: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems, attention/memory, gastrointestinal, urinary, sexual function, and miscellany. The metric attributes of this instrument were analyzed. Data from 242 patients mean age 67.2 +/- 11 years, duration of disease 6.4 +/- 6 years, and 57.3% male across all stages of PD were collected from the centers in Europe, USA, and Japan. The mean NMSS score was 56.5 +/- 40.7, (range: 0-243) and only one declared no NMS. The scale provided 99.2% complete data for the analysis with the total score being free of floor and ceiling effect. Satisfactory scaling assumptions (multitrait scaling success rate >95% for all domains except miscellany) and internal consistency were reported for most of the domains (mean alpha, 0.61). Factor analysis supported the a prori nine domain structure (63% of the variance) while a small test-retest study showed satisfactory reproducibility (ICC > 0.80) for all domains except cardiovascular (ICC = 0.45). In terms of validity, the scale showed modest association with indicators of motor symptom severity and disease progression but a high correlation with other measures of NMS (NMSQuest) and health-related quality of life measure (PDQ-8) (both, rS = 0.70). In conclusion, NMSS can be used to assess the frequency and severity of NMS in PD patients across all stages in conjunction with the recently validated non-motor questionnaire.
826 citations
••
TL;DR: The application of both scales would suggest that confusion exists on their characteristics and limitations as measures of spasticity, and there is a need to standardize methods to apply these scales in clinical practice and research.
Abstract: Background: The Ashworth Scale and the modified Ashworth Scale are the primary clinical measures of spasticity. A prerequisite for using any scale is a knowledge of its characteristics and limitations, as these will play a part in analysing and interpreting the data. Despite the current emphasis on treating spasticity, clinicians rarely measure it.Objectives: To determine the validity and the reliability of the Ashworth and modified Ashworth Scales.Study design: A theoretical analysis following a structured literature review (key words: Ashworth; Spasticity; Measurement) of 40 papers selected from the BIDS-EMBASE, First Search and Medline databases.Conclusions: The application of both scales would suggest that confusion exists on their characteristics and limitations as measures of spasticity. Resistance to passive movement is a complex measure that will be influenced by many factors, only one of which could be spasticity. The Ashworth Scale (AS) can be used as an ordinal level measure of resistance to pa...
751 citations
••
Carlos III Health Institute1, University College London2, Georgia Regents University3, Southern General Hospital4, King's College London5, Osaka University6, Fukuoka University7, University of Naples Federico II8, Tel Aviv University9, University of Pisa10, University of Cambridge11, Icahn School of Medicine at Mount Sinai12, Royal College of Nursing13, Emory University14, North Tyneside General Hospital15, St Thomas' Hospital16, Baylor College of Medicine17
TL;DR: The results gathered from 545 patients using the definitive version of the NMSQuest are presented highlighting the prevalence of the wide range of NMS flagged in the N MSQuest from consecutive PD patients in an international setting.
Abstract: 2006, there was, no single instrument (questionnaire or scale) for attempting a comprehensive assessment of the wide range of nonmotor symptoms (NMS) of Parkinson's disease (PD). The PD nonmotor group, a multidisciplinary group of experts including patient group representatives developed and validated the NMS screening questionnaire (NMSQuest) comprising 30 items. The NMSQuest is a self completed screening tool designed to draw attention to the presence of NMS. In this paper, we present the results gathered from 545 patients using the definitive version of the NMSQuest highlighting the prevalence of the wide range of NMS flagged in the NMSQuest from consecutive PD patients in an international setting.
477 citations
••
TL;DR: This multicenter clinical trial demonstrated that with contemporary antireflux therapy for GERD, either by drug-induced acid suppression with esomeprazole or by LARS, most patients achieve and remain in remission at 5 years.
Abstract: Gastroesophageal reflux disease (GERD) is a chronic, relapsing disease with symptoms that have negative effects on daily life. Two treatment options are long-term medication or surgery.
380 citations
Authors
Showing all 403 results
Name | H-index | Papers | Citations |
---|---|---|---|
David Cameron | 154 | 1586 | 126067 |
Jane Stewart | 81 | 353 | 27466 |
Louise C. Kenny | 61 | 361 | 12483 |
Richard Thomson | 59 | 219 | 21084 |
Grant Gibson | 46 | 155 | 6164 |
Helen Rodgers | 45 | 169 | 10923 |
Stephen Attwood | 45 | 132 | 10022 |
Richard Walker | 44 | 272 | 10406 |
Mike R. Reed | 38 | 129 | 4865 |
Jane Simpson | 33 | 140 | 3133 |
Christopher Price | 33 | 166 | 4542 |
Julian C. Hughes | 32 | 162 | 4390 |
Garth R. Johnson | 31 | 78 | 5190 |
Deborah Christie | 29 | 132 | 3150 |
John H. Barton | 29 | 87 | 4264 |